Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device Industry Grab-Bag Of Provisions In 21st Century Cures Draft

This article was originally published in The Gray Sheet

Executive Summary

Device industry advocates have a lot of reading to do. There are more than two dozen provisions with relevance to the medtech sector, many aimed at smoothing the way for product approvals and reimbursement, in a 21st Century Cures discussion draft unveiled by the House Energy and Commerce panel Jan. 27. The initial proposal does not have bipartisan support.

You may also be interested in...

Combo Products GMP Guidance Fills In Gaps On Drug-Delivery Device Compliance

FDA has delivered a draft current good manufacturing practices guidance for combination products, providing details and examples on how the agency regulates drug delivery devices and other drug/device, drug/biological and drug/device/biological products.

IRB, HIPAA Changes To Be Folded Into 21st Century Cures Bill Next Year

Centralized institutional review board approvals for device trials, and removal of HIPAA privacy provisions that block registry data-sharing are among the ideas that are likely to make it into a draft bill planned for release in January as the next step in the House’s 21st Century Cures initiative.

FDA’s Expedited PMA Pathway Proposal: To Expand Or Contain?

Companies want FDA to expand the bounds of its accelerated device development program, while others urge FDA to be cautious.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts